Ian Jenkins, CEO of Frelii Inc. (OTCQB: FRLI) (Frelii or The Company”) met in an informal meeting with Canadian Prime Minister, Justin Trudeau to discuss how Freliis artificial intelligence (AI) technology could be beneficial in advancing the safe and more effective use of medical cannabis products in Canada.
This was our first opportunity to meet with the prime minister, said Ian Jenkins, CEO of Frelii Inc. Frelii has been working with regulatory officials and physicians in Canada to prepare to deploy our AI technology there. It is designed to enable medical professionals and their patients to use cannabis products, such as CBD, more safely and effectively than the current, trial-and-error approach.
The use of marijuana for medical purposes has been legal in Canada since 2001. In 2018, the country became the first major world economy to legalize recreational marijuana. Because of its national laws and relaxed regulations, the country is better suited at this time for use of this technology than other countries with more prohibitive laws.
It is my opinion that Canada would be an ideal epicenter of initial wide deployment of our technology, Jenkins said. The environment is primed for expansion as the government was the first to deregulate the whole CBD space. We will be able to grow in an environment where the regulations support the expansion of a responsible approach for the safe consumption of cannabis products. Mr. Trudeau said he was encouraged that Frelii was going to deploy its technology there and opened the door for introductions to the minister of innovation, science and economic development, Navdeep Bains.
Jenkins added that the Prime Minister welcomed the opportunity for Frelii to look at Canada as a venue to expand into.
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
About Frelii Inc.
Frelii Inc. is a medical technology company that uses gene sequencing and artificial intelligence to determine risk and lifestyle modifications. Its technology analyzes the most comprehensive markers (60,000,000+) on the market to date. Freliis technology generates accurate and profoundly valuable insight into DNA. It opens opportunities never before realized in health care, precision medicine, insurance, corporate wellness as well as personal health and risk identification. For more information, please visit www.frelii.com. Frelii (OTCQB: FRLI) trades on the #OTCQB Venture Market for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com.
Follow Frelii online at:
Frelii Facebook Page https://www.facebook.com/livefrelii/ Frelii Twitter Feed @livefrelii Frelii Instagram Page @livefrelii Frelii LinkedIn Page linkedin.com/company/frelii/
Safe Harbor Statement:
This release contains certain forward-looking statements relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as believes, expects or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Companys actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Companys periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.